Kenvue Inc.

Kenvue Inc. has established itself as the world's largest pure-play consumer health company by revenue, reporting net sales of $15.1 billion for the fiscal year ended December 28, 2025. The company's integrated business model is centered on realizing the extraordinary power of everyday care through a differentiated portfolio of iconic, science-backed brands, many recommended by healthcare professionals, including Aveeno, BAND-AID Brand, Johnson's, Listerine, Neutrogena, Nicorette, Tylenol, and Zyrtec. These extensive product offerings are organized into three reportable business segments: Self Care, Skin Health and Beauty, and Essential Health, reaching consumers across over 165 countries worldwide, spanning North America, Asia Pacific, Europe, Middle East, Africa, and Latin America.

The company's operational strength is underpinned by its sophisticated capabilities and an accelerated digital strategy. Its marketing organization employs a digital-first, consumer-centric approach, leveraging precision marketing, e-commerce, and data science to generate unique consumer insights and optimize media investments. Concurrently, the research and development organization combines deep, multi-disciplinary scientific expertise with active engagement from healthcare professionals and a global network of innovation hubs, ensuring a continuous pipeline of innovative products. Kenvue maintains a global and balanced manufacturing footprint, with approximately 60% of its sales volume produced in-house, complemented by an extensive network of trusted third-party suppliers, providing operational flexibility and resilience. Kenvue operates within a highly competitive landscape, facing multinational corporations such as Haleon, Procter & Gamble, and Reckitt Benckiser Group, alongside regional players, private-label brands, and emerging niche brands across its segments.

For the fiscal year 2025, Kenvue reported net sales of $15.124 billion, a 2.1% decrease from the prior year, primarily driven by a 2.2% decline in organic sales due to volume reductions stemming from retailer inventory management in the United States, changes in shipment timing in China, and lower seasonal incidences for allergy, pediatric pain, and cough and cold products. Despite the sales decline, the company demonstrated financial resilience, with gross profit margin expanding by 10 basis points to 58.1%, benefiting from supply chain optimization initiatives. Operating income saw a substantial increase of 31.1% to $2.414 billion, and net income rose by 42.7% to $1.470 billion, largely attributable to a significant reduction in impairment charges from $578 million in 2024 to a modest $23 million in 2025. The company also achieved full independence from Johnson & Johnson in May 2024, a process that continues to involve managing separation-related costs and transitioning corporate services.

Kenvue is currently navigating a pivotal strategic juncture, primarily centered around its proposed merger with Kimberly-Clark Corporation, announced on November 2, 2025. This transaction, which has received shareholder approvals from both companies and cleared the Hart-Scott-Rodino waiting period, is expected to close in the second half of 2026, subject to foreign regulatory approvals. Upon completion, Kenvue shareholders are anticipated to own approximately 46% of the combined entity, receiving a combination of Kimberly-Clark common stock and cash for each of their Kenvue shares. This merger is poised to redefine Kenvue's market position and is expected to drive significant operational synergies and cost savings, though the successful integration of the two independent operations, corporate functions, and IT infrastructures presents a considerable execution risk.

Beyond the transformative merger, Kenvue's strategic growth initiatives are anchored by its "Our Vue Forward" restructuring program, which has substantially completed its 2024 Multi-Year Restructuring Initiative, yielding over $350 million in annualized pre-tax gross cost savings. These savings have been largely reinvested into growth opportunities, fueling brand investments and supporting the company's accelerating digital strategy, which encompasses e-commerce, connected health offerings, and the piloting of artificial intelligence tools across various functions. The company also continues to pursue global expansion initiatives and selectively engages in acquisitions and divestitures to optimize its portfolio. Kenvue's capital allocation approach balances debt management, with $8.52 billion in obligations, with shareholder returns, as evidenced by $1.58 billion in dividends paid in 2025, though its share repurchase program has been suspended due to the pending Kimberly-Clark acquisition.

However, the growth plan faces several structural headwinds and execution risks. The ongoing disentanglement from Johnson & Johnson, despite achieving full independence, still requires managing deferred asset and liability transfers in certain non-U.S. jurisdictions and securing third-party consents for contract assignments, which could lead to disruptions or less favorable terms. Furthermore, the company's continued reliance on J&J for transitional manufacturing services for key products and shared functions poses a risk should Kenvue be unable to establish comparable replacement arrangements upon the expiration of these agreements. The highly competitive consumer health market, characterized by evolving consumer preferences, increased retail trade concentration, and the rapid growth of e-commerce, demands continuous innovation and agile adaptation, presenting an ongoing challenge to market share and loyalty.

Kenvue faces a multifaceted array of material risks, prominently including those associated with its proposed merger with Kimberly-Clark, where there is no guarantee of achieving anticipated benefits, and the integration process itself poses significant operational and financial challenges, including potential loss of key employees, business disruption, and increased indebtedness for the combined entity. Beyond the merger, the company navigates a highly competitive global landscape, demanding continuous innovation and adaptation to rapidly changing consumer preferences, while its accelerating digital strategy introduces new vulnerabilities related to cybersecurity incidents, data privacy, and the evolving ethical and regulatory landscape of artificial intelligence. Operationally, reliance on third parties for manufacturing and distribution, coupled with potential supply chain disruptions, inflationary pressures, and volatility in raw material costs, poses ongoing threats to profitability and product availability. Macroeconomic factors, including geopolitical events, trade policies, and economic instability, can adversely impact consumer spending and Kenvue's financial performance, further exacerbated by foreign currency risks and the potential for goodwill and intangible asset impairment, particularly within the Skin Health and Beauty segment. Regulatory and legal risks are extensive, encompassing compliance with a broad range of global laws, ongoing legal proceedings concerning product liability (e.g., acetaminophen, talc), intellectual property protection, and complex data privacy regulations, while the lingering effects of its separation from Johnson & Johnson, including potential indemnification obligations and the need to replace transitional services, continue to present distinct challenges.

Management's forward-looking statements and overall tone reflect a strategic focus on transformation and disciplined execution, particularly highlighted by the proposed merger with Kimberly-Clark, which was unanimously approved by Kenvue's Board following a comprehensive strategic review. The leadership team emphasizes the successful completion of the "Our Vue Forward" restructuring initiative, which has generated over $350 million in annualized pre-tax gross cost savings, largely reinvested to fuel brand investments and drive sustainable, profitable growth. While specific financial guidance or targets for the combined entity post-merger are not detailed, the emphasis is on realizing operational synergies and enhancing shareholder value through the transaction. Management also underscores its robust approach to risk management, particularly in cybersecurity, which is integrated into its Enterprise Risk Management Framework with dedicated resources, training, and Board oversight, acknowledging the complexities of its global operations and the evolving digital landscape. The company's commitment to accurate financial disclosures is also evident through its responsiveness to asset performance, strategic realignments, and the correction of immaterial prior period misstatements.